RxDoctor Payments Data

Thao Mee Vang

Family · Carmichael, CANPI 1447528674

Payments from drug & device makers

$1,326in general payments, 2019–2025

Across 19 payments — averaging $69.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$376
  • Daiichi Sankyo Inc.$169
  • Stryker$159
  • Novo Nordisk$123
  • AstraZeneca$123
  • Neurocrine Biosciences, Inc.$121
  • plus $254 from 4 others

What the payments were for

  • Food & beverage$1,25094%
  • Education$766%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,326 in reported general payments places this provider in the 75th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$42,867
Medicare patients
233
Services billed
456

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide25$27,231
EliquisApixaban12$18,496
RybelsusSemaglutide19$18,202
EntrestoSacubitril/Valsartan13$8,753
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$7,937
Advair HfaFluticasone Propion/Salmeterol28$7,586
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen51$1,219
Albuterol Sulfate HfaAlbuterol Sulfate54$1,184
Estradiol13$1,057
Levothyroxine Sodium106$963
Gabapentin41$951
Pantoprazole Sodium27$601
Tamsulosin Hcl26$568
Atorvastatin Calcium63$527
Lisinopril62$518

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$123$45,43344 claims
PfizerEliquis$15$18,49612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,634 family providers in California.

Other family in Carmichael

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →